Multi-Omics Analysis of Molecular Characteristics and Carcinogenic Effect of NFE2L3 in Pan-Cancer

Mengxiao Liu; Hui Wei; Jing Yang; Xia Chen; Haoying Wang; Ya Zheng; Yuping Wang; Yongning Zhou

doi:10.3389/fgene.2022.916973

Multi-Omics Analysis of Molecular Characteristics and Carcinogenic Effect of NFE2L3 in Pan-Cancer

Front Genet. 2022 Jun 29:13:916973. doi: 10.3389/fgene.2022.916973. eCollection 2022.

Authors

Mengxiao Liu^{1

2

3}, Hui Wei^{1

2

3}, Jing Yang^{1

2

3}, Xia Chen^{1

2

3}, Haoying Wang^{1

2

3}, Ya Zheng^{2

3}, Yuping Wang^{2

3}, Yongning Zhou^{2

3}

Affiliations

¹ The First Clinical Medical College, Lanzhou University, Lanzhou, China.
² Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
³ Key Laboratory for Gastrointestinal Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China.

Abstract

NFE2L3, also known as NFE2L3, is a nuclear transcription factor associated with the pathogenesis and progression of human tumors. To systematically and comprehensively investigate the role of NFE2L3 in tumors, a pan-cancer analysis was performed using multi-omics data, including gene expression analysis, diagnostic and prognostic analysis, epigenetic methylation analysis, gene alteration analysis, immune feature analysis, functional enrichment analysis, and tumor cell functional status analysis. Furthermore, the molecular mechanism of NFE2L3 in liver hepatocellular carcinoma (LIHC) was explored. The relationship between NFE2L3 expression and survival prognosis of patients with LIHC was analyzed and a nomogram prediction model was constructed. Our study showed that NFE2L3 expression was upregulated in most cancers, suggesting that NFE2L3 may play an important role in promoting cancer progression. NFE2L3 expression is closely related to DNA methylation, genetic alteration, immune signature, and tumor cell functional status in pan-cancers. Furthermore, NFE2L3 was demonstrated to be an independent risk factor for LIHC, and the nomogram model based on NFE2L3 expression had good prediction efficiency for the overall survival of patients with LIHC. In summary, our study indicated that NFE2L3 may be an important molecular biomarker for the diagnosis and prognosis of pan-cancer. NFE2L3 is expected to be a potential molecular target for the treatment of tumors.

Keywords: DNA methylation; NFE2L3; multi-comics; pan-cancer; tumor immunity.